Showing results (21-30 of 61) with videos related to
Sort By:
Pageof 7
Diagnostic Microbiology and Infectious Disease|December 15, 2010
Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009)Michael A Pfaller, Mariana Castanheira, Shawn A Messer, et al.Diagnostic Microbiology and Infectious Disease|September 18, 2010
Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009)Michael A Pfaller, Mariana Castanheira, Shawn A Messer, et al.Journal of Clinical Microbiology|November 12, 2010
Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)Michael A Pfaller, Gary J Moet, Shawn A Messer, et al.Diagnostic Microbiology and Infectious Disease|August 5, 2021
In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 yearsMichael A Pfaller, Cecilia G Carvalhaes, Shawn A Messer, et al.The Journal of Antimicrobial Chemotherapy|November 30, 2012
Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)Michael A Pfaller, Shawn A Messer, Mary R Motyl, et al.Antimicrobial Agents and Chemotherapy|May 24, 2017
Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida SpeciesMichael A Pfaller, Shawn A Messer, Paul R Rhomberg, et al.International Journal of Antimicrobial Agents|September 15, 2019
Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate disseminationMariana Castanheira, Lalitagauri M Deshpande, Shawn A Messer, et al.Journal of Clinical Microbiology|June 11, 2010
Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008)Shawn A Messer, Ronald N Jones, Gary J Moet, et al.Antimicrobial Agents and Chemotherapy|December 12, 2012
In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methodsMichael A Pfaller, Shawn A Messer, Mary R Motyl, et al.Journal of Clinical Microbiology|June 7, 2013
In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and moldsMichael A Pfaller, Shawn A Messer, Paul R Rhomberg, et al.Pageof 7